Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Kollmann

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Basic Research in Cardiology|December 2, 1998
Hypertension and stroke--rationale behind the ACCESS trial. Acute Candesartan Cilexetil Evaluation in Stroke SurvivorsJ Schrader, M Röthemeyer, S Lüders, et al.
Oncogene|October 27, 2015
CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulationA-S Tigan, F Bellutti, K Kollmann, et al.
Leukemia|September 25, 2014
MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signalingK Kollmann, J Nangalia, W Warsch, et al.
Oncogene|February 14, 2007
JunB is a gatekeeper for B-lymphoid leukemiaR G Ott, O Simma, K Kollmann, et al.
Leukemia|May 6, 2014
Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2E Grundschober, A Hoelbl-Kovacic, N Bhagwat, et al.
Brain : a Journal of Neurology|September 11, 2012
Lysosomal dysfunction causes neurodegeneration in mucolipidosis II 'knock-in' miceK Kollmann, M Damme, S Markmann, et al.
Leukemia|October 15, 2016
A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiationK Kollmann, W Warsch, C Gonzalez-Arias, et al.
The New England Journal of Medicine|December 12, 2013
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2J Nangalia, C E Massie, E J Baxter, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Basic Research in Cardiology|December 2, 1998
Hypertension and stroke--rationale behind the ACCESS trial. Acute Candesartan Cilexetil Evaluation in Stroke SurvivorsJ Schrader, M Röthemeyer, S Lüders, et al.
Oncogene|October 27, 2015
CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulationA-S Tigan, F Bellutti, K Kollmann, et al.
Leukemia|September 25, 2014
MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signalingK Kollmann, J Nangalia, W Warsch, et al.
Oncogene|February 14, 2007
JunB is a gatekeeper for B-lymphoid leukemiaR G Ott, O Simma, K Kollmann, et al.
Leukemia|May 6, 2014
Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2E Grundschober, A Hoelbl-Kovacic, N Bhagwat, et al.
Brain : a Journal of Neurology|September 11, 2012
Lysosomal dysfunction causes neurodegeneration in mucolipidosis II 'knock-in' miceK Kollmann, M Damme, S Markmann, et al.
Leukemia|October 15, 2016
A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiationK Kollmann, W Warsch, C Gonzalez-Arias, et al.
The New England Journal of Medicine|December 12, 2013
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2J Nangalia, C E Massie, E J Baxter, et al.
Pageof 1